Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szczepanski, T.
Right arrow Articles by van Dongen, J. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szczepanski, T.
Right arrow Articles by van Dongen, J. J. M.
Related Collections
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 96 No. 3 (August 1), 2000: pp. 1087-1093

NEOPLASIA

Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgHminus subgroup of multiple myeloma

Tomasz Szczepanski, Mars B. van 't Veer, Ingrid L. M. Wolvers-Tettero, Anton W. Langerak, and Jacques J. M. van Dongen

From the Department of Immunology and Department of Hematology, Erasmus University Rotterdam/University Hospital Rotterdam, Rotterdam, The Netherlands; Department of Paediatric Haematology and Chemotherapy, Silesian Medical Academy, Zabrze, Poland.


    Abstract
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

This study involved 12 patients with multiple myeloma (MM), in whom malignant plasma cells did not contain immunoglobulin heavy chain (IgH) protein chains. Southern blot analysis revealed monoallelic JH gene rearrangements in 10 patients, biallelic rearrangement in 1 patient, and biallelic deletion of the JH and Cµ regions in 1 patient. Heteroduplex polymerase chain reaction analysis enabled the identification and sequencing of 9 clonal JH gene rearrangements. Only 4 of the joinings were complete VH-(D)-JH rearrangements, including 3 in-frame rearrangements with evidence of somatic hypermutation. Five rearrangements concerned incomplete DH-JH joinings, mainly associated with deletion of the other allele. Curiously, in at least 1 of these 5 cases the second allele seemed to be in germline configuration, whereas the in-frame Vkappa -Jkappa gene rearrangements contained somatic mutations. The configuration of the IGH genes was further investigated by use of CH probes. In 5 patients the rearrangements in the JH and CH regions were not concordant, probably caused by illegitimate IGH class switch recombination (chromosomal translocations to 14q32.3). These data indicate that in many IgH- MM patients illegitimate IGH class switch rearrangement or illegitimate deletion of the functional VH-(DH)-JH allele are responsible for IgH negativity. For example, the exclusive presence of DH-JH rearrangements in combination with mutated IGK genes can only be explained in terms of normal B-cell development, if the second (functional) IGH allele is deleted, which was probably the case in most patients. Therefore, defects at the DNA level are responsible for the lack of IgH protein production in most IgH- MM patients. (Blood. 2000;96:1087-1093)

© 2000 by The American Society of Hematology.


    Introduction
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Multiple myeloma (MM) is a clonal B-lineage malignancy affecting terminally differentiated bone marrow (BM) plasma cells bearing functional VH-(DH)-JH gene rearrangements with somatic hypermutations.1,2 The lack of intraclonal diversity in the hypermutation pattern indicates that malignant transformation occurred after positive selection in germinal centers.1,2 It has been suggested that identical clonotypic cells but having the morphology and immunophenotype of mature B cells, can be detected in peripheral blood (PB) of patients with MM.3,4 Based on extensive studies, the pathogenesis of MM is believed to be a multistep transformation process (reviewed in Hallek et al5). One of the presumably earliest oncogenic events is a translocation involving the immunoglobulin heavy chain (IGH) gene locus (chromosome 14q32.3), which is the result of illegitimate IGH class switch processes.5,6 Chromosome translocations involving IGH genes occur in most MM and several recurrent partner loci have been identified.6-15

Classical MM is characterized by the presence of osteolytic bone lesions and overproduction of structurally homogenous immunoglobulins (Ig), which can be detected as a monoclonal peak (M-protein) on serum or urine electrophoresis. Depending on the tumor mass in the BM, additional characteristic clinical features can be observed including anemia, hypercalcemia, and renal insufficiency.16 Besides the classical presentation of MM, several forms with atypical or absent M-protein are distinguishable. In up to 20% of MM cases only Ig light chain protein is detected in serum or urine without detectable Ig heavy chains (IgH): the so-called light chain (Bence-Jones) disease. In contrast, heavy chain disease is characterized by abnormally short monoclonal IgH proteins in serum without associated light chains. Nonsecretory MM without detectable M-protein in serum occurs in approximately 1% to 5% of MM patients.17-21 In about 85% of these cases intracellular Ig molecules are clearly detectable, suggesting an underlying defect in Ig excretion (nonexcretory MM), whereas the remaining 15% of cases have no detectable intracellular IgH and Ig light chains (true nonproducer MM), implying that the latter cases represent a rare subgroup (< 1% of all MM cases).18,21

The molecular background of the complete absence of IgH protein production in light chain disease and in true nonproducer MM (grouped together as IgH- MM) is not fully clarified. We aimed therefore at identifying the molecular features responsible for the absence of IgH protein synthesis in IgH- MM.


    Patients, materials, and methods
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Patients

Bone marrow (n = 9), PB (n = 1), or tissue biopsies (n = 2; 1 skin biopsy and 1 tonsil) were obtained from 12 MM patients, aged 35 to 78 years, without production of IgH protein chains at initial diagnosis or during the course of their disease. Morphologic examination of the cell samples revealed that the percentages of plasma cells ranged from 20% to 90%. In 9 patients the plasma cells produced Ig light chain proteins, whereas in the other 3 patients no evidence for Ig light chain production was found. The latter 3 patients (MM-10, MM-11, and MM-12) were diagnosed as true nonproducer MM. Immunoelectrophoresis demonstrated that in all 9 patients with monoclonal CyIgkappa + or CyIglambda + plasma cells monoclonal Ig light chains were present in serum or urine or both at the time of investigation. Two patients (MM-4 and MM-8) showed high frequencies of plasma cells in their PB. In the other 10 patients no plasma cells were found in PB on cytomorphologic examination.

Immunophenotyping of mononuclear cells (MNC) and plasma cells in tissue biopsies

Mononuclear cells were isolated from BM or PB samples by Ficoll (density 1.077 g/mL; Pharmacia, Uppsala, Sweden) density centrifugation. In patients MM-10 and MM-11, snap frozen skin and tonsil biopsies, respectively, were used for immunohistology and molecular studies.

The MNC of the 10 BM or PB samples as well as the tissue biopsies from patients MM-10 and MM-11 were analyzed for surface expression of CD10 (VIL-A1), CD19 (Leu-12), CD38 (Leu-17) antigen, and HLA-DR (L243) as well as for cytoplasmic expression of IgM, IgD, IgG, IgA, IgE, Igkappa , and Iglambda . The Leu monoclonal antibodies and anti-HLA-DR antibody were obtained from Becton Dickinson (San Jose, CA) and VIL-A1 was a gift from Dr W. Knapp (Vienna, Austria). The antihuman Ig antibodies were polyspecific and obtained from Nordic Immunological Laboratories (Tilburg, The Netherlands). The monoclonal antibodies were used in indirect immunofluorescence assays with a fluorescein isothiocyanate (FITC)-conjugated goat antimouse Ig serum (Central Laboratory Blood Transfusion Service, Amsterdam, The Netherlands) as second-step reagent. The antihuman Ig antibodies were directly conjugated with either FITC or tetrahodamine isothiocyanate (TRITC) and used for IgH/Igkappa or IgH/Iglambda double stainings to confirm the absence of cytoplasmic IgM, IgD, IgG, IgA, and IgE protein chains in the Ig light chain-positive MM cells. Fluorescence stainings were evaluated using fluorescence microscopes (Zeiss, Oberkochen, Germany).22

Southern blot analysis

DNA was isolated from frozen MNC (n = 10) or from tissue samples (n = 2), digested, and blotted to nylon membranes as described previously.23

IGH gene rearrangements were studied by use of 32P labeled IGHJ6, Cµ, Cgamma , Calpha , and Cepsilon probes.24-28 The IGHJ6 probe (DAKO Corporation, Carpinteria, CA) was used in BglII and BamHI/HindIII digests and in EcoRI, HindIII, or BamHI digests for confirmation. The Cµ probe was used in BamHI digests, whereas the other CH probes were used in EcoRI, HindIII, or BamHI digests.23

The IGK gene rearrangements were studied with the 32P-labeled IGKJ5, IGKC, and IGKDE probes (DAKO).29 The IGKJ5 probe was used in EcoRI, HindIII, BglII, and BamHI digests, whereas the IGKC and IGKDE probes were used in BglII and BamHI digests.29

The IGL gene rearrangements were studied with the 32P-labeled IGLC3 probe (DAKO), which detects 95% of all Jlambda -Clambda gene rearrangements in EcoRI/HindIII digests.30

Polymerase chain reaction (PCR) amplification and heteroduplex analysis of PCR products

The PCR analysis was essentially performed as described previously.31,32 In each 50 µL PCR reaction 50 ng DNA sample, 6.3 pmol of the 5' and 3' oligonucleotide primers, and 0.5 U AmpliTaq Gold polymerase (PE Biosystems, Foster City, CA) were used. The sequences of the oligonucleotides used for amplification of complete VH-JH and incomplete DH-JH gene rearrangements as well as for Vkappa -Jkappa rearrangements were published previously.33-36 PCR conditions were: preactivation of the enzyme for 10 minutes at 94°C, followed by 35 cycles of 45 seconds at 92°C, 90 seconds at 60°C, and 2 minutes at 72°C using a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last cycle an additional extension step of 10 minutes at 72°C was performed. Appropriate positive and negative controls were included in all experiments.32

To distinguish between polyclonal and monoclonal rearrangements we performed heteroduplex analysis of the obtained PCR products. In short, the PCR products were denatured at 94°C for 5 minutes to obtain single-stranded PCR products. Subsequently the single-stranded products were cooled to 4°C for 60 minutes to induce random renaturation (duplex formation).37 In case of monoclonal gene rearrangements homoduplexes are formed (identical junctional regions), whereas heteroduplexes are found in case of polyclonal gene rearrangements (heterogeneous junctional regions). The obtained duplexes were immediately loaded on 6% nondenaturing polyacrylamide gels in 0.5 × Tris-borate-EDTA (TBE) buffer, run at room temperature, and visualized by ethidium bromide staining to discriminate between the presence of rapidly migrating homoduplex bands or slowly migrating heteroduplexes smears.37 A 100-bp DNA ladder (Promega Corporation, Madison, WI) was used as size marker.

Sequence analysis of IGH and IGK gene rearrangements

Clonal PCR products as found by heteroduplex analysis were directly sequenced. Sequencing was performed using the dye-terminator cycle sequencing kit with AmpliTaq DNA polymerase FS on an ABI 377 sequencer (PE Biosystems) as described before.34 VH, Vkappa , DH, JH and Jkappa segments were identified using DNAPLOT software (W. Müller, H-H. Althaus, University of Cologne, Germany) by searching for homology with all known human germline VH, Vkappa , DH, JH, and Jkappa sequences obtained from the VBASE directory of human Ig genes (http://www.mrc-cpe.cam.ac.uk/imt-doc/).38

Northern blot analysis

Total RNA was isolated with the LiCl/urea method39 from frozen MNC of BM samples from 6 patients with light chain MM of whom sufficient cells were available. Fifteen micrograms of total RNA was size-fractionated in 1.0% agarose gel containing formaldehyde and transferred to a Biodyne nylon membrane (Pall Ultrafine Filtration Corp, Glen Cove, NY). The above-mentioned Ckappa , Cµ, Cgamma , Calpha , and Cepsilon DNA probes were used for detection of IGK and IGH transcripts. Total RNA from the human B-cell lines ROS-17, EB4B, ROS-15, and U266 were used as positive controls for the detection of IgM, IgG, IgA, and IgE transcripts, respectively.


    Results
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Immunophenotyping

Immunophenotyping of the MNC from the 9 light chain MM patients and the nonproducer patient MM-12 as well as immunohistology of the skin and tonsil biopsies from the other 2 nonproducer patients (MM-10 and MM-11) demonstrated that the malignant plasma cells in all 12 patients did not contain IgH chains, whereas Igkappa chain and Iglambda chains were found in the plasma cells from 8 patients (MM-1 to MM-8) and 1 patient (MM-9), respectively (Table 1). In 3 patients (MM-10, MM-11, and MM-12) neither Igkappa nor Iglambda chains were detected (Table 1). The plasma cells in all 12 patients were negative in CD10, CD19, and HLA-DR staining, but positive in CD38 staining.

                              
View this table:
[in this window]
[in a new window]
  		Table 1. IGH gene configuration in MM patients based on Southern blotting, heteroduplex PCR analysis, and sequencing

Configuration of IGH genes

In 10 patients clonal rearrangements of JH gene segments were found on only 1 allele (MM-1 to MM-7, MM-9, MM-10, and MM-12), in 1 patient on both alleles (patient MM-11), and in 1 case (patient MM-8) the JH and Cµ regions were deleted on both alleles (Table 1, Figure 1). In some patients the presence of normal non-B cells with germline IGH genes might hamper the detection of a monoallelic IGH gene deletion. However, based on the percentages of malignant plasma cells and the relative density of rearranged and germline bands, the absence or presence of a deleted second allele could be estimated in most cases. In fact, we concluded that in at least 4 of the 10 patients with monoallelic JH rearrangements the second allele was deleted, that in 2 additional patients the second allele might be deleted, whereas in the other 4 patients the second IGH allele seemed to be in germline configuration (Figure 1).


View larger version (54K):
[in this window]
[in a new window]
  		Fig 1. IGH and IGK gene configuration of 6 IgH-/Igkappa + MM patients. (A) IGHJ6 probe hybridization to BglII digests or BamHI/HindIII digests. (B) IGKJ5 probe hybridization to EcoRI digests.

Detailed heteroduplex PCR analysis of the IGH locus was performed in 11 patients using 19 primer combinations (6 IGH framework-1 VH-family specific primers, 6 VH-leader primers, and 7 family-specific DH primers in combination with 1 JH consensus primer). In a total of 9 patients 9 monoclonal homoduplexes were found out of the total 12 JH gene rearrangements as identified by Southern blotting; in 1 patient (MM-3) insufficient DNA was available for detailed PCR studies, and PCR analyses in 2 other patients (MM-2 and MM-11) failed to detect a JH rearrangement (Table 1; Figure 2). Only 4 of the detected JH rearrangements were complete VH-(DH)-JH rearrangements and sequence analysis revealed 4 different functional VH gene segments (VH1-18, VH1-24, VH2-5, and VH3-11). Three of these rearrangements were in a proper reading frame with evidence of somatic hypermutation (patients MM-1, MM-9, and MM-12), whereas the fourth rearrangement was out-of-frame and unmutated (patient MM-11). Five rearrangements concerned incomplete DH-JH joinings, using 4 different DH gene segments (DH1-26, DH2-2, DH3-16, and DH4-23). In 2 of these 5 cases the second IGH allele was deleted, in 2 other cases the second allele might be deleted, whereas in 1 case the second allele seemed to be germline. Based on the knowledge of the gene segments identified in the clonal PCR products together with the complete sequence of the human IGH locus,40,41 the theoretical sizes of restriction fragments containing the respective rearrangements were calculated and indeed found to be concordant with the sizes of the respective rearranged bands in Southern blot analysis.


View larger version (64K):
[in this window]
[in a new window]
  		Fig 2. Heteroduplex PCR analysis in several IgH- MM patients to distinguish between polyclonal and monoclonal IGH and IGK gene rearrangements. Clonal homoduplexes found with particular primer combinations are illustrated as compared to positive controls. In patient MM-1, the size of the homoduplex found with the VH1-JH PCR was essentially larger than predicted. Sequence analysis showed a PCR product with a VH1-24/JH3 rearrangement extended to the JH5 segment with extensive somatic hypermutation of the JH3 gene (resulting in loss of the primer annealing site) and deletion of the JH4 segment most probably owing to an abnormal somatic mutation process.48

The configuration of the IGH genes was further investigated by use of Cµ, Cgamma , Calpha , and Cepsilon probes (Table 1). In 7 patients a rearranged Cµ gene band was found, which comigrated with the JH band in 5 of them (patients MM-3, MM-4, MM-6, MM-7, and MM-10), indicating that no IGH class switch had occurred; at least 4 of these 5 rearrangements concerned a DH-JH joining (patient MM-3 was not studied by PCR), which explains the absence of IGH class switch. In the other 2 cases (patients MM-1 and MM-9) the rearranged JH and Cµ regions were not present on the same restriction fragments, suggesting that illegitimate recombination with a breakpoint in the JH-Cµ area had occurred thereby making the in-frame VH-JH joining in these 2 patients nonfunctional. The Southern blot analyses with the Cgamma probe did not provide reliable information concerning rearrangements and IGH class switch, due to the complex banding pattern, which is caused by the 5 Cgamma gene segments and their genetic polymorphisms.23 Nevertheless, in patient MM-2 the Cgamma probe allowed the detection of Cgamma gene deletions, which could be explained by a presumably normal IGH class switch to Calpha , whereas in patient MM-5 extensive illegitimate Cgamma gene deletions were found on 1 allele. Analyses with the Calpha probe revealed a monoallelic rearrangement in 5 of the 12 patients. In patients MM-2 and MM-12, the rearranged bands comigrated with a rearranged JH gene band, suggesting that an IgA class switch had occurred. In the other 3 patients (patients MM-5, MM-8, and MM-11) no proof for close linkage between the JH region and the rearranged Calpha region was found, which might be due to illegitimate IGH class switches. Finally, in 1 case (patient MM-3) a rearranged band was found with the Cepsilon probe. This patient contained a JH-Cµ rearrangement on 1 allele with deletion of the JH region on the other allele. The latter suggests that the detected Cepsilon rearrangement might be caused by deletion of a large part of the IGH locus.

Configuration of IGK and IGL genes

In 6 of the 8 Igkappa + MM patients a monoallelic rearrangement in the Jkappa -Ckappa area was found (Figure 1), while the Jkappa -Ckappa region on the second allele was in germline configuration in 5 patients and deleted in the sixth patient (MM-2), owing to a Vkappa to kappa deleting element (Kde) rearrangement (Table 2). In the remaining 2 Igkappa + patients (MM-3 and MM-4), Vkappa -Jkappa rearrangements were found on 1 allele; the other allele contained a Vkappa -Jkappa rearrangement in combination with a Ckappa deletion. Both IGL alleles were in germline configuration in all 8 Igkappa + patients. The patient with Iglambda light chain MM had biallelic IGL gene rearrangements in combination with biallelic nonfunctional IGK gene rearrangements owing to intron RSS-Kde and Vkappa -Kde recombinations.

                              
View this table:
[in this window]
[in a new window]
  		Table 2. Ig light chain gene configuration in MM patients based on Southern blotting, heteroduplex PCR analysis, and sequencing

Two nonproducer MM patients (MM-10 and MM-11) had a monoallelic Vkappa -Jkappa gene rearrangement with the IGL genes in germline configuration. Interestingly, the third nonproducer MM patient (MM-12) had biallelic IGK rearrangements with deleted Ckappa segments on both alleles (intron RSS-Kde recombinations) and biallelic IGL gene rearrangements.

Heteroduplex PCR analysis of Vkappa -Jkappa gene rearrangements was performed in 11 patients with 4 Vkappa family-specific primers and 2 Jkappa reverse primers. Eleven monoclonal homoduplexes were found in 10 patients (Table 2 and Figure 2), including 8 in-frame rearrangements with moderate amounts of somatic mutations and 3 out-of-frame unmutated joinings. In the true nonproducer MM-10 no clonal Vkappa -Jkappa PCR products could be identified, whereas in nonproducer MM-11 the identified Vkappa -Jkappa gene rearrangement was in-frame.

Transcription of Ig genes

Six patients with Igkappa + light chain MM (patients MM-1, MM-2, MM-3, MM-4, MM-5, and MM-6) could be studied for the occurrence of Ig messenger RNA (mRNA) by use of Northern blot analysis. As expected, in all 6 patients high levels of IGK mRNA were present. In patient MM-1 a trace IGM mRNA, high levels of IGG mRNA and low levels of IGA mRNA were found. In patient MM-2 no IGH transcripts were detected. In patient MM-3 we found trace levels of IGM and IGG transcripts, which were essentially lower than the IGK mRNA transcription levels, thereby suggesting that these low IGH transcript levels were probably derived from the background of normal B cells. In patients MM-4 and MM-6 low or moderate levels of IGM transcripts were detected. Finally, in patient MM-5 a trace of IGG mRNA and moderate levels of truncated IGA mRNA were found. IGE mRNA could not be detected in all 6 tested patients.


    Discussion
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Lack of IgH protein synthesis may be caused by abnormalities at several levels, for example, abnormalities at the DNA level (a defective gene with true nonsynthetic capability), aberrant transcription processes, aberrant translation processes, or rapid degradation of newly synthesized IgH protein.21 We mainly focused on detailed molecular analysis of the IGH genes. Although seemingly normal JH gene rearrangements were found in all but 1 patient by Southern blotting, the further PCR-based identification of these rearrangements as well as Southern blot analysis of the downstream part of the IGH locus with probes for the various constant gene segments revealed distinct molecular abnormalities explaining the absence of IgH proteins (summarized in Table 3).

                              
View this table:
[in this window]
[in a new window]
  		Table 3. Molecular abnormalities responsible for IgH negativity in the 12 MM patients

Southern blot analysis in 10 MM patients showed clonal JH rearrangements on only 1 allele. This is in striking contrast to normal B-cell development and most B-lineage malignancies, where IGH gene rearrangements are generally found on both alleles.42-44 Therefore, one would have expected biallelic IGH gene rearrangements in most MM cases. In patient MM-8 both JH alleles were deleted, which is an obvious reason for IgH negativity in this case. In 5 patients (MM-1, MM-3, MM-5, MM-9, and MM-11) the rearranged JH gene and CH gene segments were not linked, suggesting that illegitimate class switch recombination had separated the rearranged (VH)-DH-JH complex from a CH gene segment. This phenomenon can explain the IgH negativity in patients MM-1 and MM-9 with functional (in-frame) somatically mutated VH-(DH)-JH rearrangements. In patient MM-3 the illegitimate switch recombination resulted in the deletion of 1 JH allele, whereas the second IGH allele, probably nonfunctional, did not undergo class switch. Unfortunately, we could not perform PCR/sequencing analysis due to insufficient DNA, but Northern blotting showed absence of the expected IGH mRNA levels in patient MM-3. In patients MM-5 and MM-11 additional reasons were found for IgH protein negativity, that is, an incomplete DH-JH rearrangement and an out-of-frame VH-(DH)-JH rearrangement, respectively (Table 3). The causative mechanism underlying the aberrant CH rearrangements in the above 5 patients is most probably a translocation involving the IGH gene on chromosome 14q32.3, known to occur frequently in MM. Unfortunately, no cytogenetic data are available in our group of patients. Although chromosome aberrations with breakpoints in the CH region of the IGH locus occur in the majority of MM patients, they seem to affect IgH protein production only in rare cases.6,8 In IgH+ MM cases such translocations presumably occur on the nonproductive allele or involve switch regions downstream of a functional VH-(DH)-JH-C complex.5 Even biallelic translocations involving IGH genes may be accompanied by a normal IgH+ phenotype.8,45 Nevertheless, our data clearly show that in at least 2 (but probably 3) of our patients an illegitimate class switch rearrangement seems to be the sole cause of the absence of IgH proteins, whereas in additional 2 cases, it appeared to be one of the causes for IgH negativity (Table 3).

In patient MM-2 extensive heteroduplex PCR analysis did not reveal any clonal IGH gene rearrangement and also Northern blotting showed no IGH gene transcription. This indicates that the JH gene rearrangement found by Southern blotting in this patient might also reflect an illegitimate recombination. In fact, translocations to JH gene segments (rather than to the switch regions) owing to abnormal V(D)J recombinase activity occur frequently in some subsets of non-Hodgkin lymphomas, but were previously also suggested to occur in MM and found in the MM-derived cell line FLAM-76.6,11,46

Remarkably, in 5 patients heteroduplex PCR analysis showed that the single IGH-JH rearrangement detected by Southern blotting concerned an incomplete DH-JH joining. In 2 of these patients (patients MM-4 and MM-5) the second allele (most probably having contained a functional VH-(DH)-JH gene rearrangement) was deleted. However, in the remaining 3 patients Southern blot analysis suggested that the second allele might be in germline configuration, although we cannot exclude deletion of the second allele in 2 of the 3 cases because of the low tumor load (Table 1, Figure 1). Curiously, the 4 Igkappa + positive MM patients with incomplete DH-JH rearrangements had functional, somatically mutated IGK gene rearrangements. We cannot explain this finding in terms of normal B-cell maturation because exclusive DH-JH rearrangements, as found in our patients, are markers of the most immature B-cell precursors in BM and are in striking contrast with somatically mutated Vkappa -Jkappa gene rearrangements, which are typical for mature Ig+ (post-)germinal B cells. In fact, from an immunobiologic point of view, the precursor of each plasma cell and each MM should originally have expressed a functional Ig molecule to reach its final stage of B-cell maturation. Therefore, the most likely explanation for the absence of a functional IGH gene rearrangement in the 5 patients with exclusive DH-JH rearrangements has to be that the second (functional) allele was deleted during or after the oncogenic process. This was indeed found in patients MM-4 and MM-5, might be true in patients MM-7 and MM-10, but seems not to be the case in patient MM-6 (Table 1). The high frequency of monoallelic IGH gene rearrangements (10 of 12 cases) already suggested that in IgH- MM deletion of 1 IGH allele is a frequent phenomenon.

Finally, we could not establish the reason for IgH negativity in 1 case (patient MM-12). Although on 1 allele JH and Cµ gene segments were deleted, the second allele contained a functional, in-frame, somatically mutated VH1-18/JH4 rearrangement linked to a Calpha gene. Unfortunately, Northern blot analysis could not be performed due to insufficient cell material.

One of the few studies addressing the potential mechanisms for inability of IgH protein production in Bence-Jones MM, demonstrated lack of IGH transcription in 6 IgH- MM cases and 3 IgH- MM cell lines.47 The authors suggested alterations of the transcriptional apparatus as a major cause of failure to produce IgH. However their analysis of the IGH gene configuration was too limited to exclude defects at the DNA level. Kuipers et al46 used several fluorescence in situ hybridization techniques for studying 19 MM cell lines, including 11 without IgH protein production. They concluded that the majority of IgH- cell lines contained abnormal IGH genes owing to illegitimate IGH class switch processes, presumably resulting from chromosome translocations involving 14q32.3. Curiously, 6 of 11 IgH- cell lines were derived from Ig-producing MM patients. Therefore, secondary genetic changes during culturing might have caused IgH negativity in these cell lines.

The combined Southern blot and PCR data presented here show that in the vast majority of IgH- MM patients defects at the DNA level are responsible for the lack of IgH protein production. We conclude that in at least 9 of the 12 patients (Table 3) these defects concern illegitimate IGH class switch rearrangements or illegitimate deletion of the functional VH-(DH)-JH allele, which probably occurred during or after the malignant transformation process.


    Acknowledgments

We are grateful to Prof dr R. Benner and Prof dr D. Sonta-Jakimczyk for their continuous support, Mr T. M. van Os for preparation of the figures and Mrs A. D. Korpershoek for her secretarial support.


    Footnotes

Submitted December 27, 1999; accepted March 30, 2000.

Reprints: J. J. M. van Dongen, Department of Immunology, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.


    References
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

1. Baker BW, Deane M, Gilleece MH, Johnston D, Scarffe JH, Norton JD. Distinctive features of immunoglobulin heavy chain variable region gene rearrangement in multiple myeloma. Leuk Lymphoma. 1994;14:291-301[Medline] [Order article via Infotrieve].

2. Vescio RA, Cao J, Hong CH, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol. 1995;155:2487-2497[Abstract].

3. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 1998;92:2844-2855[Abstract/Free Full Text].

4. Mitterer M, Oduncu F, Lanthaler AJ, et al. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. Br J Haematol. 1999;106:737-743[Medline] [Order article via Infotrieve].

5. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21[Free Full Text].

6. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A. 1996;93:13931-13936[Abstract/Free Full Text].

7. Lai JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85:2490-2497[Abstract/Free Full Text].

8. Nishida K, Tamura A, Nakazawa N, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1997;90:526-534[Abstract/Free Full Text].

9. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 1997;90:4062-4070[Abstract/Free Full Text].

10. Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 1998;92:4269-4278[Abstract/Free Full Text].

11. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998;101:296-301[Medline] [Order article via Infotrieve].

12. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457-4463[Abstract/Free Full Text].

13. Rao PH, Cigudosa JC, Ning Y, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood. 1998;92:1743-1748[Abstract/Free Full Text].

14. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998;58:5640-5645[Abstract/Free Full Text].

15. Proffitt J, Fenton J, Pratt G, Yates Z, Morgan G. Isolation and characterisation of recombination events involving immunoglobulin heavy chain switch regions in multiple myeloma using long distance vectorette PCR (LDV-PCR). Leukemia. 1999;13:1100-1107[Medline] [Order article via Infotrieve].

16. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma---new biological insights and advances in therapy. Blood. 1989;73:865-879[Abstract/Free Full Text].

17. Dreicer R, Alexanian R. Nonsecretory multiple myeloma. Am J Hematol. 1982;13:313-318[Medline] [Order article via Infotrieve].

18. Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma: presenting findings, clinical course and prognosis. Acta Haematol. 1985;74:27-30[Medline] [Order article via Infotrieve].

19. Rubio-Felix D, Giralt M, Giraldo MP, et al. Nonsecretory multiple myeloma. Cancer. 1987;59:1847-1852[Medline] [Order article via Infotrieve].

20. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037[Abstract/Free Full Text].

21. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259-1272[Medline] [Order article via Infotrieve].

22. Van Dongen JJM, Adriaansen HJ, Hooijkaas H. Immunological marker analysis of cells in the various hematopoietic differentiation stages and their malignant counterparts. In: Ruiter DJ,Fleuren GJ,Warnaar SO, eds. Application of Monoclonal Antibodies in Tumor Pathology. Dordrecht: Martinus Nijhoff; 1987:87-116.

23. Van Dongen JJM, Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects. Clin Chim Acta. 1991;198:1-91[Medline] [Order article via Infotrieve].

24. Beishuizen A, Verhoeven MA, Mol EJ, Breit TM, Wolvers-Tettero ILM, van Dongen JJM. Detection of immunoglobulin heavy-chain gene rearrangements by Southern blot analysis: recommendations for optimal results. Leukemia. 1993;7:2045-2053[Medline] [Order article via Infotrieve].

25. Ravetch JV, Kirsch IR, Leder P. Evolutionary approach to the question of immunoglobulin heavy chain switching: evidence from cloned human and mouse genes. Proc Natl Acad Sci U S A. 1980;77:6734-6738[Abstract/Free Full Text].

26. Rabbitts TH, Forster A, Milstein CP. Human immunoglobulin heavy chain genes: evolutionary comparisons of C mu, C delta and C gamma genes and associated switch sequences. Nucleic Acids Res. 1981;9:4509-4524[Abstract/Free Full Text].

27. Krawinkel U, Rabbitts TH. Comparison of the hinge-coding segments in human immunoglobulin gamma heavy chain genes and the linkage of the gamma 2 and gamma 4 subclass genes. EMBO J. 1982;1:403-407[Medline] [Order article via Infotrieve].

28. Max EE, Battey J, Ney R, Kirsch IR, Leder P. Duplication and deletion in the human immunoglobulin epsilon genes. Cell. 1982;29:691-699[Medline] [Order article via Infotrieve].

29. Beishuizen A, Verhoeven MA, Mol EJ, van Dongen JJM. Detection of immunoglobulin kappa light-chain gene rearrangement patterns by Southern blot analysis. Leukemia. 1994;8:2228-2236[Medline] [Order article via Infotrieve].

30. Tümkaya T, Comans-Bitter WM, Verhoeven MA, van Dongen JJM. Southern blot detection of immunoglobulin lambda light chain gene rearrangements for clonality studies. Leukemia. 1995;9:2127-2132[Medline] [Order article via Infotrieve].

31. Szczepanski T, Langerak AW, Wolvers-Tettero ILM, et al. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease. Leukemia. 1998;12:1081-1088[Medline] [Order article via Infotrieve].

32. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized MRD detection in ALL using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:110-118[Medline] [Order article via Infotrieve].

33. Aubin J, Davi F, Nguyen-Salomon F, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia. 1995;9:471-479[Medline] [Order article via Infotrieve].

34. Szczepanski T, Pongers-Willemse MJ, Langerak AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood. 1999;93:4079-4085[Abstract/Free Full Text].

35. Beishuizen A, de Bruijn MAC, Pongers-Willemse MJ, et al. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia. 1997;11:2200-2207[Medline] [Order article via Infotrieve].

36. Klein U, Klein G, Ehlin-Henriksson B, Rajewsky K, Kuppers R. Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes. Mol Med. 1995;1:495-505[Medline] [Order article via Infotrieve].

37. Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero ILM, van Dongen JJM. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia. 1997;11:2192-2199[Medline] [Order article via Infotrieve].

38. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today. 1995;16:237-242[Medline] [Order article via Infotrieve].

39. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, a Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.

40. Corbett SJ, Tomlinson IM, Sonnhammer ELL, Buck D, Winter G. Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination. J Mol Biol. 1997;270:587-597[Medline] [Order article via Infotrieve].

41. Ma